Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

Παρόμοια τεκμήρια

• Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians
  ανά: Kuemmerle-Deschner, Jasmin B., κ.ά.
  Έκδοση: (2013)
• Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
  ανά: Bader-Meunier, B, κ.ά.
  Έκδοση: (2011)
• Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
  ανά: Brogan, Paul A., κ.ά.
  Έκδοση: (2019)
• A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
  ανά: Hansmann, Sandra, κ.ά.
  Έκδοση: (2011)
• Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
  ανά: Kuemmerle-Deschner, J, κ.ά.
  Έκδοση: (2015)